BIRC6 promotes hepatocellular carcinogenesis: Interaction of BIRC6 with p53 facilitating p53 degradation

The genes that encode inhibitor of apoptosis proteins (IAPs) are frequently overexpressed in human cancers. However, the expression pattern and clinical significance of BIRC6, a member of IAPs, in hepatocellular carcinoma (HCC) remains unclear. Here we investigated the role of BIRC6 in hepatocellular carcinogenesis. We used immunoblot and immunochemical analyses to determine the levels of BIRC6 in 7 hepatoma cell lines and 160 HCC specimens. We evaluated the proognostic value of BIRC6 expression and its association with clinical parameters. A lentivirus‐mediated silencing method was used to knockdown BIRC6, and the biological consequences of BIRC6 silencing in three hepatoma cell lines were investigated in vitro and in vivo. We found that BIRC6 overexpression was significantly correlated with serum ALT level and HCC vascular invasion. Patients with positive BIRC6 expression in tumor tissue had a poor survival and a high rate of recurrence. BIRC6 knockdown remarkably suppressed cell proliferation, caused G1/S arrest and sensitized hepatoma cells to sorafenib‐induced apoptosis in hepatoma cells, which was partly reversed by RNA interference targeting p53. The mechanistic study revealed that BIRC6 interacted with p53 and facilitated its degradation. The in vivo study showed that BIRC6 knockdown inhibited xenograft tumor growth and increased the sensitivity of tumor cells to sorafenib in nude mice. Taken together, these findings demonstate that BIRC6 overexpression in HCC specimens is indicative of poor prognosis and that its interaction with p53 facilitates the degradation of p53, leading to carcinogenesis and an anti‐apoptotic status.

[1]  S. Giordano,et al.  Met as a therapeutic target in HCC: facts and hopes. , 2014, Journal of hepatology.

[2]  X. Shen,et al.  Expression and clinical significance of BIRC6 in human epithelial ovarian cancer , 2014, Tumor Biology.

[3]  M. Gleave,et al.  BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells , 2013, PloS one.

[4]  S. Lam,et al.  Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  F. Speleman,et al.  Identification of BIRC6 as a novel intervention target for neuroblastoma therapy , 2012, BMC Cancer.

[6]  N. Zaffaroni,et al.  Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways , 2012, Clinical Cancer Research.

[7]  A. Adly,et al.  BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis , 2012, European journal of haematology.

[8]  S. Kaul,et al.  Induction of mutant p53‐dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin , 2011, International journal of cancer.

[9]  Rebecca SY Wong,et al.  Apoptosis in cancer: from pathogenesis to treatment , 2011, Journal of experimental & clinical cancer research : CR.

[10]  H. Clevers,et al.  Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target* , 2011, Molecular & Cellular Proteomics.

[11]  Ling Dong,et al.  Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2011, Acta biochimica et biophysica Sinica.

[12]  V. Graupner,et al.  Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level , 2011, Cell Death and Differentiation.

[13]  David Lane,et al.  p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.

[14]  Chunsheng Zhang,et al.  Targeting cadherin‐17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma , 2009, Hepatology.

[15]  S. Qiu,et al.  CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery , 2009, Clinical Cancer Research.

[16]  M. Daidone,et al.  Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation , 2009, British Journal of Cancer.

[17]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[18]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[19]  Christian Pohl,et al.  Final Stages of Cytokinesis and Midbody Ring Formation Are Controlled by BRUCE , 2008, Cell.

[20]  N. Kato,et al.  Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus , 2007, Hepatology.

[21]  Hee-Jin Kim,et al.  Overexpression of Apollon, an Antiapoptotic Protein, Is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia , 2007, Clinical Cancer Research.

[22]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[23]  P. Carinci,et al.  Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. , 2006, International journal of oncology.

[24]  D. Brash,et al.  Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-xL reduction thereby enhancing UV-light induced apoptosis , 2005, Oncogene.

[25]  W. Skarnes,et al.  The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Goldberg,et al.  The Membrane-associated Inhibitor of Apoptosis Protein, BRUCE/Apollon, Antagonizes Both the Precursor and Mature Forms of Smac and Caspase-9* , 2005, Journal of Biological Chemistry.

[27]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[28]  O. Yokosuka,et al.  Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. , 2004, Journal of hepatology.

[29]  T. Noda,et al.  Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function , 2004, Nature Cell Biology.

[30]  S. Jentsch,et al.  Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. , 2004, Molecular cell.

[31]  T. Takayama,et al.  Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. , 2003, Cancer research.

[32]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[33]  Michael Berger,et al.  Apoptosis - the p53 network , 2003, Journal of Cell Science.

[34]  G. E. Davis,et al.  A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis , 2001, Apoptosis.

[35]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[36]  D. Green,et al.  p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release* , 2000, The Journal of Biological Chemistry.

[37]  T. Tsuruo,et al.  A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.

[38]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[39]  S. Friend,et al.  Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. , 1995, Oncogene.

[40]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[41]  R. Metcalf,et al.  p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.

[42]  N. Zaffaroni,et al.  RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy. , 2012, Current topics in medicinal chemistry.

[43]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[44]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[45]  V. Rotter,et al.  Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.

[46]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.